dc.date.accessioned | 2023-11-17T16:48:08Z | |
dc.date.available | 2023-11-17T16:48:08Z | |
dc.date.created | 2023-11-01T10:38:36Z | |
dc.date.issued | 2023 | |
dc.identifier.citation | Gunst, Jesper D. Højen, Jesper F. Pahus, Marie H. Rosás-Umbert, Miriam Stiksrud, Birgitte McMahon, James H. Denton, Paul W. Nielsen, Henrik Johansen, Isik S. Benfield, Thomas Leth, Steffen Gerstoft, Jan Østergaard, Lars Schleimann, Mariane H. Olesen, Rikke Støvring, Henrik Vibholm, Line Weis, Nina Dyrhol-Riise, Anne Ma Pedersen, Karen B. H. Lau, Jillian S. Y. Copertino, Dennis C. Linden, Noemi Huynh, Tan T. Ramos, Victor Jones, R. Brad Lewin, Sharon R. Tolstrup, Martin Rasmussen, Thomas A. Nussenzweig, Michel C. Caskey, Marina Reikvam, Dag Henrik Søgaard, Ole S. . Impact of a TLR9 agonist and broadly neutralizing antibodies on HIV-1 persistence: the randomized phase 2a TITAN trial. Nature Medicine. 2023, 29(10), 2547-2558 | |
dc.identifier.uri | http://hdl.handle.net/10852/105933 | |
dc.description.abstract | Inducing antiretroviral therapy (ART)-free virological control is a critical step toward a human immunodeficiency virus type 1 (HIV-1) cure. In this phase 2a, placebo-controlled, double-blinded trial, 43 people (85% males) with HIV-1 on ART were randomized to (1) placebo/placebo, (2) lefitolimod (TLR9 agonist)/placebo, (3) placebo/broadly neutralizing anti-HIV-1 antibodies (bNAbs) or (4) lefitolimod/bNAb. ART interruption (ATI) started at week 3. Lefitolimod was administered once weekly for the first 8 weeks, and bNAbs were administered twice, 1 d before and 3 weeks after ATI. The primary endpoint was time to loss of virologic control after ATI. The median delay in time to loss of virologic control compared to the placebo/placebo group was 0.5 weeks (P = 0.49), 12.5 weeks (P = 0.003) and 9.5 weeks (P = 0.004) in the lefitolimod/placebo, placebo/bNAb and lefitolimod/bNAb groups, respectively. Among secondary endpoints, viral doubling time was slower for bNAb groups compared to non-bNAb groups, and the interventions were overall safe. We observed no added benefit of lefitolimod. Despite subtherapeutic plasma bNAb levels, 36% (4/11) in the placebo/bNAb group compared to 0% (0/10) in the placebo/placebo group maintained virologic control after the 25-week ATI. Although immunotherapy with lefitolimod did not lead to ART-free HIV-1 control, bNAbs may be important components in future HIV-1 curative strategies. ClinicalTrials.gov identifier: NCT03837756. | |
dc.language | EN | |
dc.publisher | Nature Portfolio | |
dc.rights | Attribution 4.0 International | |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0/ | |
dc.title | Impact of a TLR9 agonist and broadly neutralizing antibodies on HIV-1 persistence: the randomized phase 2a TITAN trial | |
dc.title.alternative | ENEngelskEnglishImpact of a TLR9 agonist and broadly neutralizing antibodies on HIV-1 persistence: the randomized phase 2a TITAN trial | |
dc.type | Journal article | |
dc.creator.author | Gunst, Jesper D. | |
dc.creator.author | Højen, Jesper F. | |
dc.creator.author | Pahus, Marie H. | |
dc.creator.author | Rosás-Umbert, Miriam | |
dc.creator.author | Stiksrud, Birgitte | |
dc.creator.author | McMahon, James H. | |
dc.creator.author | Denton, Paul W. | |
dc.creator.author | Nielsen, Henrik | |
dc.creator.author | Johansen, Isik S. | |
dc.creator.author | Benfield, Thomas | |
dc.creator.author | Leth, Steffen | |
dc.creator.author | Gerstoft, Jan | |
dc.creator.author | Østergaard, Lars | |
dc.creator.author | Schleimann, Mariane H. | |
dc.creator.author | Olesen, Rikke | |
dc.creator.author | Støvring, Henrik | |
dc.creator.author | Vibholm, Line | |
dc.creator.author | Weis, Nina | |
dc.creator.author | Dyrhol-Riise, Anne Ma | |
dc.creator.author | Pedersen, Karen B. H. | |
dc.creator.author | Lau, Jillian S. Y. | |
dc.creator.author | Copertino, Dennis C. | |
dc.creator.author | Linden, Noemi | |
dc.creator.author | Huynh, Tan T. | |
dc.creator.author | Ramos, Victor | |
dc.creator.author | Jones, R. Brad | |
dc.creator.author | Lewin, Sharon R. | |
dc.creator.author | Tolstrup, Martin | |
dc.creator.author | Rasmussen, Thomas A. | |
dc.creator.author | Nussenzweig, Michel C. | |
dc.creator.author | Caskey, Marina | |
dc.creator.author | Reikvam, Dag Henrik | |
dc.creator.author | Søgaard, Ole S. | |
cristin.unitcode | 185,53,11,14 | |
cristin.unitname | Infeksjonsmedisinsk avdeling | |
cristin.ispublished | true | |
cristin.fulltext | original | |
cristin.qualitycode | 2 | |
dc.identifier.cristin | 2190931 | |
dc.identifier.bibliographiccitation | info:ofi/fmt:kev:mtx:ctx&ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Nature Medicine&rft.volume=29&rft.spage=2547&rft.date=2023 | |
dc.identifier.jtitle | Nature Medicine | |
dc.identifier.volume | 29 | |
dc.identifier.issue | 10 | |
dc.identifier.startpage | 2547 | |
dc.identifier.endpage | 2558 | |
dc.identifier.doi | https://doi.org/10.1038/s41591-023-02547-6 | |
dc.type.document | Tidsskriftartikkel | |
dc.type.peerreviewed | Peer reviewed | |
dc.source.issn | 1078-8956 | |
dc.type.version | PublishedVersion | |